HIV R4P: Positive Response to "Gift Tokens for Undetectable Viral Load" Trial

A U.S. study presented at last month’s HIV Research for Prevention conference found generally positive responses among people with HIV and clinic staff to a trial that used $70 gift tokens as an incentive for people to attend clinic visits regularly, refill their HIV treatment prescriptions, and maintain an undetectable viral load. However, the study found that only just under half of patients had an accurate understanding of what viral load was, and that this did not improve during the study.


Delaying Treatment More than 12 Months after HIV Infection Reduces CD4 Cell Recovery

People with HIV who start antiretroviral therapy (ART) more than a year after seroconversion have a lower likelihood of regaining normal CD4 T-cell counts, researchers reported in the November 24 online edition of JAMA Internal Medicine. "If full restoration of immunologic and clinical health is our goal, then the present study tells us that the best chance we have is to start antiretroviral therapy within 12 months of infection," according to an accompanying editorial.


Complete Coverage of HIV Drug Therapy 2014 coverage of the HIV Drug Therapy 2014 Conference Research, November 2-6, 2014, in Glasgow, Scotland.

Full listing of coverage by topic

HIV Drug Therapy 2014 website



People with HIV and Uninfected People Diagnosed with Age-related Diseases at Similar Ages

HIV positive people are more likely than HIV negative individuals to have heart attacks and develop end-stage kidney disease and non-AIDS cancers in the era of effective antiretroviral therapy, but they do so at around the same ages, on average, according to study of U.S. veterans published in the October 30 edition of Clinical Infectious Diseases.


HIV Drug Therapy: Once-daily Dolutegravir Superior to Darunavir at 96 Weeks

Treatment with a triple antiretroviral combination containing the once-daily integrase inhibitor dolutegravir (Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir (Prezista) over 96 weeks of follow-up, Jean-Michel Molina of the Hôpital Saint Louis, Paris, reported this month at the HIV Drug Therapy Glasgow conference.


HIV R4P: RV144 HIV Vaccine's Effects Were Real -- and Could Be Made to Work Better

Findings from further studies using a reformulation of the only HIV vaccine that has ever worked in a large efficacy trial were presented at the recent HIV Research for Prevention conference (HIVR4P) in Cape Town. They showed evidence of stronger antibody responses, and in-depth analysis of these responses suggests that by further developing a similar vaccine, it may be possible to push the immune system to generate an antibody response to HIV that is sufficiently strong to prevent most infections.


HIV R4P: The Immunity Project -- An Open-Access T-Cell Vaccine for HIV Infection

Microparticles containing conserved HIV epitopes may be able to prime antigen-presenting dendritic cells, which in turn activate antigen-specific CD8 killer T-cells, offering a potential new approach for developing T-cell-based preventive or therapeutic HIV vaccines, researchers with the open-access Immunity Project reported at the HIV Research for Prevention (HIV R4P) conference last week in Cape Town.